Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 7/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.36 |
| ▸ | CDC42BPB | Q9Y5S2 | 5/20 | 0.36 |
| ▸ | CDC42BPA | Q5VT25 | 4/20 | 0.36 |
| ▸ | GSK3B | P49841 | 2/20 | 0.35 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.35 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.35 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.32 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15718817 | 0.81 | MAPK1 (0.41) | MAPK1DYRK1A | |
| Quinoline SCHEMBL27950148 | 0.70 | ALDH1A1 (0.49) | MAPK1DYRK1ALRRK2GSK3BNFATC1 | |
| SCHEMBL1473042 | 0.69 | MAPK1 (0.45) | MAPK1DYRK1AEGFRERBB2ERBB3 | |
| SCHEMBL21938395 | 0.69 | MAPK1 (0.45) | MAPK1DYRK1A | |
| SCHEMBL30167002 | 0.69 | MAPK1 (0.45) | MAPK1DYRK1AEGFRERBB2ERBB3 | |
| SCHEMBL24348992 | 0.69 | MAPK1 (0.45) | MAPK1DYRK1A | |
| SCHEMBL1473269 | 0.69 | DYRK1A (0.53) | MAPK1DYRK1ALRRK2EGFRERBB2 | |
| SCHEMBL2628882 | 0.69 | MAPK1 (0.45) | MAPK1DYRK1A | |
| SCHEMBL29691438 | 0.69 | DYRK1A (0.53) | MAPK1DYRK1ALRRK2EGFRERBB2 | |
| SCHEMBL27813658 | 0.69 | PRKCI (0.48) | MAPK1DYRK1AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240270757-A1 | SPIROCYCLIC COMPOUNDS | ASTRAZENECA AB (SE) | 2024-08-15 | — | — | US | disclosed |
| US-20230357279-A1 | SPIROCYCLIC COMPOUNDS | ASTRAZENECA AB (SE) | 2023-11-09 | — | — | US | disclosed |
| EP-3489237-B1 | 4-AZAINDOLE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2020-05-13 | — | — | EP | disclosed |
| EP-3489237-B1 | 4-AZAINDOLE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2020-05-13 | — | — | EP | disclosed |
| EP-3489237-A1 | 4-AZAINDOLE DERIVATIVES | Eisai R&D Management Co., Ltd. (JP) | 2019-05-29 | — | — | EP | disclosed |
| EP-3489237-A1 | 4-AZAINDOLE DERIVATIVES | Eisai R&D Management Co., Ltd. (JP) | 2019-05-29 | — | — | EP | disclosed |
| EP-3052496-B1 | 4-AZAINDOLE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2018-11-28 | — | — | EP | disclosed |
| US-10072005-B2 | 4-azaindole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-09-11 | — | — | US | disclosed |
| US-20180208593-A1 | 4-Azaindole Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-07-26 | — | — | US | disclosed |
| US-20180208593-A1 | 4-Azaindole Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-07-26 | — | — | US | disclosed |
| US-20090306095-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-10 | — | — | US | disclosed |
| US-7501420-B2 | Composition and antiviral of substituted azaindoleoxoacetic piperazine derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501420-B2 | Composition and antiviral of substituted azaindoleoxoacetic piperazine derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-03-10 | — | — | US | disclosed |
| US-20080188481-A1 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC 4-ALKENYL PIPERIDINE AMIDES | BRISTOL-MYERS SQUIBB COMPANY | 2008-08-07 | — | — | US | disclosed |
| US-20080132516-A1 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC N-SUBSTITUTED PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-05 | — | — | US | disclosed |
| US-20080132516-A1 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC N-SUBSTITUTED PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-05 | — | — | US | disclosed |
| US-20080119480-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-22 | — | — | US | disclosed |
| US-20080119480-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-22 | — | — | US | disclosed |
| US-7354924-B2 | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-04-08 | — | — | US | disclosed |
| US-7354924-B2 | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306095-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | ITPA, IDO1, IDO2 | MAPK1 4706/4885DYRK1A 4605/4885LRRK2 4151/4885 |
| US-20240270757-A1 | SPIROCYCLIC COMPOUNDS | PKD1, PKD2, CCNI | MAPK1 785/4885DYRK1A 3331/4885LRRK2 2082/4885 |
| US-20080188481-A1 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC 4-ALKENYL PIPERIDINE AMIDES | IDO1, IDO2, INMT | MAPK1 4672/4885DYRK1A 4148/4885LRRK2 1734/4885 |
| US-10072005-B2 | 4-azaindole derivatives | CHRM1, CHRM4, CHRM2 | MAPK1 3364/4885DYRK1A 523/4885LRRK2 104/4885 |
| US-20080119480-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | ITPA, IDO1, IDO2 | MAPK1 4706/4885DYRK1A 4605/4885LRRK2 4151/4885 |
| US-20180208593-A1 | 4-Azaindole Derivatives | CHRM1, CHRM4, CHRM2 | MAPK1 3364/4885DYRK1A 523/4885LRRK2 104/4885 |
| US-20080132516-A1 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC N-SUBSTITUTED PIPERAZINE DERIVATIVES | IDO2, IDO1, INMT | MAPK1 4541/4885DYRK1A 3163/4885LRRK2 4211/4885 |
| US-20230357279-A1 | SPIROCYCLIC COMPOUNDS | PKD1, PKD2, CCNI | MAPK1 785/4885DYRK1A 3331/4885LRRK2 2082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.